Long-term Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) who Discontinue Ibrutinib

INTRODUCTION: Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, approved for the treatment of patients with chronic lymphocytic leukemia in frontline and relapsed-refractory settings. We previously reported poor outcomes for patients discontinuing ibrutinib; however, long term outcomes were n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Jain, Preetesh, Thompson, Philip A, Keating, Michael, Estrov, Zeev, Ferrajoli, Alessandra, Jain, Nitin, Kantarjian, Hagop, Burger, Jan, O’Brien, Susan, Wierda, William G.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980235/
https://ncbi.nlm.nih.gov/pubmed/28171709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30596
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky